Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_assertion type Assertion NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_head.
- NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_assertion description "[A total of 209 consecutive patients with stage IV nonsquamous NSCLC with an EGFR (epidermal growth factor receptor) mutation (N = 39), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation (N = 49), ALK (anaplastic lymphoma receptor tyrosine kinase) gene rearrangement (N = 41), or wild-type for all 3 (triple negative, N = 80) were included.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_provenance.
- NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_assertion evidence source_evidence_literature NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_provenance.
- NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_assertion SIO_000772 22282022 NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_provenance.
- NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_assertion wasDerivedFrom befree-20150227 NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_provenance.
- NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_assertion wasGeneratedBy ECO_0000203 NP609706.RAL_vKQblpn-Ot3E0Fy4J2mkbSQVDO2Mud169KU7pwdRY130_provenance.